Tag: Eli Lilly

Lilly Completes Acquisition of Dermira

lilly
Eli Lilly and Company announced the successful completion of its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigat...

FDA Granted Priority Review Status for the NDA for Selpercatinib

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of patie...

FDA Approves Trijardy XR for Type 2 Diabetes in Adults

The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, a...

Lilly Will Invest More Than $470 Million to Build New Manufacturing

lilly
Eli Lilly and Company, a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs in Durham, Governor Roy Cooper announced Jan. 21. The project ...

Eli Lilly to Acquire Dermira for $1.1 Billion

Eli Lilly and Company and Dermira, Inc. Jan. 10 announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction. Dermira i...

U.S. Court Supported Eli Lilly in Alimta Vitamin Regimen Patent Lawsuit

Eli Lilly and Company announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta® (pemetrexed for injection) vitamin regimen patent would be in...

Eli Lilly Unveiled First Shared Innovation Lab in San Francisco

laboratory
Eli Lilly and Company unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech compani...

Eli Lilly to Invest $400m in Indianapolis Manufacturing Facilities

Eli Lilly and Company announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by increasing demand for Lilly'...

Eli Lilly’s Cancer Drug Failed in Clinical Trials

eli lilly
Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in phase 3 pancreatic cancer trial. The big US pharma said top-line results from the phase 3 SEQUO...

Eli Lilly Announced Positive Results from Phase 3 RELAY trial of CYRAMZA®

Eli Lilly and Company announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSC...

Eli Lilly Announced New Data Showing Taltz® Superiority versus TREMFYA®

Eli Lilly and Company presented new detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an I...

FDA Accepted Eli Lilly Application to Enter CID Pilot Meeting Program

Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting Program, an initiative which ...

FDA Approved Eli Lilly’s Taltz® Injection

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis (AS)...

Biosimilar Teriparatide Launches in Europe by Gedeon Richter

gedeon-richter
A biosimilar to Eli Lilly’s Forsteo, biosimilar teriparatide, has been launched across Europe by Gedeon Richter following the patent expiration of the reference product, it was revealed on Aug. 20, 20...

Arbitration Panel Ruled in Favor of Eli Lilly in Complaint Filed by Adocia

A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on rapid-acting insulin. The panel of ...

Positive Results for Eli Lilly’s Emgality® from CONQUER Study Announced

Eli Lilly and Company announced that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the prev...